Cytostatic drugs and their carcinogenicity - Occupational risk problem for healthcare workers;Leki cytostatyczne i ich kancerogenność - Problem zagrożenia zawodowego personelu medycznego

Wspolczesna Onkologia

Volumn 11, Issue 2, 2007, Pages 101-103

  Dabrowski, Tomasz ^a   Dabrowska, Ewa Anna ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Cancer risk; Carcinogenicity; Cytostatic drugs; Occupational exposure

Indexed keywords

CYTOSTATIC AGENT;

ARTICLE; CANCER RISK; DRUG CARCINOGENICITY; HEALTH CARE PERSONNEL; HEALTH HAZARD; HUMAN; MAXIMUM ALLOWABLE CONCENTRATION; MUTAGENIC ACTIVITY; OCCUPATIONAL DISEASE; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; PATIENT CARE; TERATOGENESIS;

EID: 34247892317     PISSN: 14282526     EISSN: 14282526     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Walusiak J, Wagrowska-Koski E, Pałczyński C. Ocena skutków zdrowotnych zawodowej ekspozycji na cytostatyki u personelu medycznego w świetle obowiazujacej profilaktyki: Badanie przekrojowe. Med Pr 2003; 54: 229-36.
2. Falck K, Grohn P, Sorsa M, Vainio H, Heinonen E, Holsti LR. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet 1979; 1: 1250-1.
3. NIOSH, Alert Document Preventing Occupational Exposure to Antineoplastic and other Hazardous Drugs in Health Care Settings, US Department of Health and Human Service, Public Occupational Safety and Health DHHS, 2004, NIOSH Publication No. 2004-165.
4. Oplolka S, Molter W, Goldschmidt R. Evaporation of cytostatic drugs during preparation. Occup Health Ind Med 1998; 39: 207-8.
5. Laidlaw JL, Connor TH, Theiss JC, Anderson RW, Matney TS. Permeability of latex and polyvinyl chloride gloves to 20 antineoplastic drugs. Am J Hosp Pharm 1984; 41: 2618-23.
6. Kromhout H, Hoek F, Uitterhoeve R, Huijbers R, Overmars RF, Anzion R, Vermeulen R. Postulating a dermal pathway for exposure to antineoplastic drugs among hospital workers. Applying a conceptual model to the results of three workplace surveys. Ann Occup Hyg 2000; 44: 551-60.
7. Erlichman Ch, Moore M. Clinical studies implicating antineoplastic agents in carcinogenesis. W: Cancer chemotherapy and biotherapy: Principles and practices. Chabner BA, Longo DL (eds). Lippincott Williams and Wilkins 2001; 72-74.
8. Skov T, Maarup B, Olsen J, Rorth M, Winthereik H, Lynge E. Leukaemia and reproductive outcome among nurses handling antineoplastic drugs. Br J Ind Med 1992; 49: 855-61.
9. Sorsa M, Anderson D. Monitoring of occupational exposure to cytostatic anticancer agents. Mutat Res 1996; 355: 253-61.
10. Dann EJ, Rowe JM. Biology and therapy of secondary leukaemias. Best Pract Res Clin Haematol 2001; 14: 119-37.
11. Skov T, Lynge E, Maarup B, Olsen J, Rorth M, Winthereik H. Risks for physicians handling antineoplastic drugs. Lancet 1990; 336: 1446.
12. Hansen J, Olsen JH. Cancer morbidity among Danish female pharmacy technicians. Scand J Work Environ Health 1994; 20: 22-26.
13. Bonassi S, Abbondandolo A, Camurri L, et al. Are chromosome aberrations in circulating lymphocytes predictive of future cancer onset in humans? Preliminary results of an Italian cohort study. Cancer Genet Cytogenet 1995; 79: 133-5.
14. Levin LI, Holly EA, Seward JP. Bladder cancer in a 39-year-old female pharmacist. J Natl Cancer Inst 1993; 85: 1089-91.
15. Sessink PJ, Kroese ED, van Kranen HJ, Bos RP. Cancer risk assessment for health care workers occupationally exposed to cyclophosphamide. Int Arch Occup Environ Health 1995; 67: 317-23.
16. Turci R, Sottani C, Spagnoli G, Minoia C. Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: a review of analytical methods. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 789: 169-209.
17. Czerczak S. Klasyfikacje chemicznych czynników rakotwórczych - przeglad. Bezpieczeństwo Pracy - Nauka i Praktyka 2004; 33(1): 9-14.